

Amendments to the Specification:

Please amend the specification as follows:

Page 2, replace paragraph [0006] with the following paragraph:

[0006] [Non-patent Literature 1] Christopher W. A. et al., (2002) Current Opinion in Immunology ~~12:323-330~~ 14:323-330

[Non-patent Literature 2] Horak I., (1995) Clinical Immunology and Immunopathology Sep; 76(3 Pt 2): S172-3

Page 36, replace paragraph [0096] with the following paragraph:

[0096] Single expression of PKC theta AE which was activated as the phosphorylation enzyme results in six times higher NF-kappa B transcription activity than that with PKC theta ~~AE~~ KR alone, which proves adequacy of the experimental system. It is also demonstrated that co-expression of PKC theta AE and KPNA1 results in elevation of transcription activity of NF-kappa B as the expression of KPNA1 increases. The expression was further elevated to 6.4 times that of PKC theta AE alone. These phenomena were not observed at all with co-expression of PKC theta KR which is inactivated as the phosphorylation enzyme together with KPNA1, and expression of KPNA1 alone.